City of Hope presents pivotal clinical trial data on potential new therapy for acute leukemias
Revumenib, an orally administered cancer medicine known as a menin inhibitor, showed safety and efficacy in a key Phase 2 study in adult and pediatric patients with relapsed/refractory acute myeloid leukemia (AML), acute lymphoid leukemia (ALL) and mixed phenotype leukemia